Cardiometabolic Diseases Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Treatment, Dosage, Route of Administration, End Users, Distribution Channel and Geography

Cardiometabolic Diseases Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Treatment, Dosage, Route of Administration, End Users, Distribution Channel and Geography

  • October 2021 •
  • 293 pages •
  • Report ID: 6195568 •
  • Format: PDF
The cardiometabolic diseases market is expected to reach US$ 121,804.49 million by 2028 from US$ 93,494.41 million in 2021; it is estimated to grow at a CAGR of 3.9% during 2021–2028. The report highlights trends prevailing in the market and factors driving its growth. The market growth is mainly attributed to factors such as increasing prevalence of cardiometabolic diseases and innovation in CMDs therapeutics. However, the underdiagnosis of CVDs in low- and middle-income countries (LMICs) is hampering the growth of the market.

The prevention, control, and management of CMDs and their risk factors create substantial public health challenges requiring advanced approaches to be integrated in public health programs.Advancements in computers, electronics, telecommunication, and medicines have resulted in rapid development of health-related technology.

For instance, the genomic prevention approach can identify people at risk of developing the disease, allowing early intervention for high-risk individuals to make lifestyle changes.In March 2021, NHS started trials for genomic testing to predict the risk of heart disease.

With NHS, the UK biotech firm and Oxford University spin-off, Genomics plc is working on a pilot study that will use genetic information to predict the risk level of heart diseases.An integrated risk tool (IRT), created by Genomics plc, will be used to estimate each patient’s risk of developing a CVD within the next 10 years.

The company has claimed that if the IRT is applied to everybody aged between 40 and 60 in the UK, it could identify more than 650,000 people at high risk of CVDs, missed by current screening. Apart from this, recent advances on the Internet of Things (IoT), cloud computing, and artificial intelligence (AI) have significantly improved the conventional healthcare system. In August 2021, South Ural State University (SUSU) scientists have developed a model for more effective diagnosis of CVDs and diabetes, using AI and IoT.

Moreover, the integration of AI is further offering lucrative opportunities for the growth of the worldwide cardiometabolic disease market and is expected to continue supporting this market over the forecast period. In June 2021, The ACC and GE Healthcare collaborated through the support of and participation in ACC’s Applied Health Innovation Consortium (AHIC) to build a roadmap for AI and digital technology in cardiology and develop new strategies for improved health outcomes.

The cardiometabolic diseases market, by type, is segmented into cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity.The cardiovascular disease (CVD) segment is expected to hold the largest share and register the highest CAGR in the market during the forecast period.

Based on treatment, the market is segmented into ACE inhibitors, diuretics, Glucophage, and others.The ACE inhibitors segment held the largest share of the market in 2021, and the same segment is anticipated to register the highest CAGR in the market during the forecast period.

The cardiometabolic diseases market, based on dosage, is bifurcated into tablet and injection.The tablet segment held a larger share of the market in 2021 and is anticipated to register a higher CAGR in the market during the forecast period.

Based on route of administration, the market is bifurcated into oral and intravenous. In 2021, the oral segment held a larger market share and is expected to register a higher CAGR in the market during the forecast period. Based on end users, the market is segmented into clinic, hospital, and homecare setting. In 2021, the hospital segment held the largest share of the market and is anticipated to register the highest CAGR in the market during the forecast period. Based on distribution channel, the cardiometabolic diseases market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2021, the hospital pharmacy segment held the largest market share. The same segment is expected to register the highest CAGR in the market during the forecast period.

A few of the major primary and secondary sources referred to while preparing the report on the cardiometabolic diseases market are the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), International Diabetes Federation (IDF), and the National Center for Biotechnology Information (NCBI).
Loading...

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.